Drug Profile


Alternative Names: Ad5/3-D24-GMCSF; CGTG-102; ONCOS102

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncos Therapeutics
  • Developer Ludwig Institute for Cancer Research; MedImmune; Oncos Therapeutics; SOTIO; Targovax
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Ovarian cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Mesothelioma
  • Phase I/II Colorectal cancer; Ovarian cancer; Prostate cancer
  • Phase I Malignant melanoma; Soft tissue sarcoma
  • No development reported Solid tumours

Most Recent Events

  • 12 Jun 2018 Phase-II clinical trials in Mesothelioma (Combination therapy, Inoperable/Unresectable) in Spain (Intratumoural) before June 2018
  • 02 May 2018 Preliminary efficacy data from a phase I/II trial in Mesothelioma (Combination therapy, Inoperable/Unresectable) released by Targovax
  • 02 May 2018 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Czech Republic (Intratumoural) (NCT03514836) (EudraCT2015-004314-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top